BDBM324336 (R)-5-(tert-butyl)-N-(2- (cyclopropylmethyl)-8- (2-((1-methyl-1H- pyrazol-4- yl)amino)pyrimidin-4- yl)-2,3,4,5-tetrahydro- 1H-benzo[c]azepin-5- yl)-1,3,4-oxadiazole-2- carboxamide::US10189829, Compound 107::US10227341, Compound 107::US10961237, Compound 107::US11858926, Compound 107

SMILES Cn1cc(Nc2nccc(n2)-c2ccc3[C@@H](CCN(CC4CC4)Cc3c2)NC(=O)c2nnc(o2)C(C)(C)C)cn1

InChI Key InChIKey=NWWLDCUSTIGCTA-XMMPIXPASA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 324336   

TargetTyrosine-protein kinase BTK [14-552](Homo sapiens (Human))
Biogen Ma

US Patent
LigandPNGBDBM324336((R)-5-(tert-butyl)-N-(2- (cyclopropylmethyl)-8- (2...)
Affinity DataIC50: <1nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent